Literature DB >> 19114671

In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.

Steven D Brown1, Maria M Traczewski.   

Abstract

The spectrum of activity of ceftaroline was evaluated against 1,247 bacterial isolates representing 44 different species or phenotypic groups. For the majority of species, the activity of ceftaroline was comparable or superior to that of ceftriaxone. MIC and/or disk diffusion quality control ranges of ceftaroline were determined for five standard ATCC reference strains.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19114671      PMCID： PMC2650548          DOI： 10.1128/AAC.01021-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

Authors:  Ronald N Jones; Thomas R Fritsche; Yigong Ge; Koné Kaniga; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2005-10-20       Impact factor: 5.790

2.  Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Authors:  Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

5.  TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties.

Authors:  Tomoyasu Ishikawa; Nobuyuki Matsunaga; Hiroyuki Tawada; Noritaka Kuroda; Yutaka Nakayama; Yukio Ishibashi; Mitsumi Tomimoto; Yukihiro Ikeda; Yoshihiko Tagawa; Yuji Iizawa; Kenji Okonogi; Shohei Hashiguchi; Akio Miyake
Journal:  Bioorg Med Chem       Date:  2003-05-29       Impact factor: 3.641

6.  Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics.

Authors:  Adriel Villegas-Estrada; Mijoon Lee; Dusan Hesek; Sergei B Vakulenko; Shahriar Mobashery
Journal:  J Am Chem Soc       Date:  2008-06-27       Impact factor: 15.419

7.  In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.

Authors:  Cédric Jacqueline; Jocelyne Caillon; Virginie Le Mabecque; Anne-Françoise Miègeville; Antoine Hamel; Denis Bugnon; James Yigong Ge; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

8.  Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.

Authors:  George H Talbot; Dirk Thye; Anita Das; Yigong Ge
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

9.  In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

Authors:  Shazad Mushtaq; Marina Warner; Yigong Ge; Koné Kaniga; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2007-06-04       Impact factor: 5.790

10.  In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

Authors:  Yuji Iizawa; Junko Nagai; Tomoyasu Ishikawa; Shohei Hashiguchi; Masafumi Nakao; Akio Miyake; Kenji Okonogi
Journal:  J Infect Chemother       Date:  2004-06       Impact factor: 2.211
  10 in total
  12 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

2.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.

Authors:  Louis Saravolatz; Joan Pawlak; Leonard Johnson
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

4.  In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

Authors:  James A Karlowsky; Heather J Adam; Melanie R Decorby; Philippe R S Lagacé-Wiens; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

5.  Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Christopher Duplessis; Nancy F Crum-Cianflone
Journal:  Clin Med Rev Ther       Date:  2011-02-10

Review 6.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Authors:  James A Karlowsky; Heather J Adam; Melanie R Baxter; Philippe R S Lagacé-Wiens; Andrew J Walkty; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

8.  Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.

Authors:  Diego J Maselli; Juan F Fernandez; Christine Y Whong; Kelly Echevarria; Anoop M Nambiar; Antonio Anzueto; Marcos I Restrepo
Journal:  Infect Drug Resist       Date:  2012-02-01       Impact factor: 4.003

9.  Ceftaroline in complicated skin and skin-structure infections.

Authors:  Paul O Hernandez; Sergio Lema; Stephen K Tyring; Natalia Mendoza
Journal:  Infect Drug Resist       Date:  2012-01-19       Impact factor: 4.003

10.  Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.

Authors:  Julian J Goodman; Stanley I Martin
Journal:  Ther Clin Risk Manag       Date:  2012-03-26       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.